| Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin JB Carroll, SC Warby, AL Southwell, CN Doty, S Greenlee, N Skotte, ... Molecular Therapy 19 (12), 2178-2185, 2011 | 311 | 2011 |
| CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup SC Warby, A Montpetit, AR Hayden, JB Carroll, SL Butland, H Visscher, ... The American Journal of Human Genetics 84 (3), 351-366, 2009 | 285 | 2009 |
| Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease PR Joshi, NP Wu, VM André, DM Cummings, C Cepeda, JA Joyce, ... Journal of Neuroscience 29 (8), 2414-2427, 2009 | 197 | 2009 |
| Automated deformation analysis in the YAC128 Huntington disease mouse model JP Lerch, JB Carroll, S Spring, LN Bertram, C Schwab, MR Hayden, ... Neuroimage 39 (1), 32-39, 2008 | 179 | 2008 |
| Treating the whole body in Huntington's disease JB Carroll, GP Bates, J Steffan, C Saft, SJ Tabrizi The Lancet Neurology 14 (11), 1135-1142, 2015 | 177 | 2015 |
| Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes M Valenza, V Leoni, JM Karasinska, L Petricca, J Fan, J Carroll, ... Journal of Neuroscience 30 (32), 10844-10850, 2010 | 169 | 2010 |
| Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus SC Warby, CN Doty, RK Graham, JB Carroll, YZ Yang, RR Singaraja, ... Human molecular genetics 17 (15), 2390-2404, 2008 | 160 | 2008 |
| In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides AL Southwell, NH Skotte, HB Kordasiewicz, ME Østergaard, AT Watt, ... Molecular Therapy 22 (12), 2093-2106, 2014 | 150 | 2014 |
| Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients NH Skotte, AL Southwell, ME Østergaard, JB Carroll, SC Warby, CN Doty, ... PloS one 9 (9), e107434, 2014 | 149 | 2014 |
| Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo RK Graham, Y Deng, J Carroll, K Vaid, C Cowan, MA Pouladi, M Metzler, ... Journal of Neuroscience 30 (45), 15019-15029, 2010 | 137 | 2010 |
| Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease JP Lerch, JB Carroll, A Dorr, S Spring, AC Evans, MR Hayden, JG Sled, ... Neuroimage 41 (2), 243-251, 2008 | 134 | 2008 |
| Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation M Valenza, JB Carroll, V Leoni, LN Bertram, I Björkhem, RR Singaraja, ... Human molecular genetics 16 (18), 2187-2198, 2007 | 132 | 2007 |
| Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain JM Van Raamsdonk, M Metzler, E Slow, J Pearson, C Schwab, J Carroll, ... Neurobiology of disease 26 (1), 189-200, 2007 | 128 | 2007 |
| A fully humanized transgenic mouse model of Huntington disease AL Southwell, SC Warby, JB Carroll, CN Doty, NH Skotte, W Zhang, ... Human molecular genetics 22 (1), 18-34, 2013 | 124 | 2013 |
| Antisense oligonucleotides extend survival of prion-infected mice GJ Raymond, HT Zhao, B Race, LD Raymond, K Williams, EE Swayze, ... JCI insight 4 (16), 2019 | 100 | 2019 |
| Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease JB Carroll, JP Lerch, S Franciosi, A Spreeuw, N Bissada, RM Henkelman, ... Neurobiology of disease 43 (1), 257-265, 2011 | 94 | 2011 |
| Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14 K Huang, SS Sanders, R Kang, JB Carroll, L Sutton, J Wan, R Singaraja, ... Human Molecular Genetics 20 (17), 3356-3365, 2011 | 91 | 2011 |
| Parvoviral nuclear import: bypassing the host nuclear-transport machinery S Cohen, AR Behzad, JB Carroll, N Pante Journal of general virology 87 (11), 3209-3213, 2006 | 87 | 2006 |
| Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints EV Minikel, HT Zhao, J Le, J O’Moore, R Pitstick, S Graffam, GA Carlson, ... Nucleic acids research 48 (19), 10615-10631, 2020 | 84 | 2020 |
| Transcriptional regulatory networks underlying gene expression changes in Huntington's disease SA Ament, JR Pearl, JP Cantle, RM Bragg, PJ Skene, SR Coffey, ... Molecular systems biology 14 (3), e7435, 2018 | 67 | 2018 |
Michael HaydenKillam Professor, University of British ColumbiaVerified email at cmmt.ubc.ca
